Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
624.96
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
argenx to Present at Upcoming Investor Conferences
November 26, 2024
From
argenx SE
Via
GlobeNewswire
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
November 20, 2024
From
argenx SE
Via
GlobeNewswire
(ARGX) - Analyzing argenx's Short Interest
November 14, 2024
Via
Benzinga
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
November 12, 2024
Via
Benzinga
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
November 11, 2024
From
Zai Lab Limited
Via
Business Wire
Peering Into argenx's Recent Short Interest
November 06, 2024
Via
Benzinga
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
November 11, 2024
From
argenx SE
Via
GlobeNewswire
This eBay Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
November 05, 2024
Via
Benzinga
argenx to Participate at Upcoming Investor Conferences
November 05, 2024
From
argenx SE
Via
GlobeNewswire
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'
November 01, 2024
Argenx SE ADR shares jumped after impressive earnings. Analysts raised price targets and noted strong pipeline and global expansion.
Via
Benzinga
This Atlassian Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
November 01, 2024
Via
Benzinga
The Latest Analyst Ratings For argenx
October 17, 2024
Via
Benzinga
Peeling Back The Layers: Exploring argenx Through Analyst Insights
September 26, 2024
Via
Benzinga
What 25 Analyst Ratings Have To Say About argenx
August 23, 2024
Via
Benzinga
This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
November 01, 2024
Via
Benzinga
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
October 31, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
October 24, 2024
From
argenx SE
Via
GlobeNewswire
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
October 15, 2024
From
argenx SE
Via
GlobeNewswire
The Analyst Verdict: argenx In The Eyes Of 27 Experts
July 29, 2024
Via
Benzinga
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
October 01, 2024
Biotech bull market is intact as indicated by large cap biopharma and the best performing funds.
Via
Talk Markets
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
September 25, 2024
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
Via
Investor's Business Daily
Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
September 24, 2024
Via
Benzinga
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
September 19, 2024
From
argenx SE
Via
GlobeNewswire
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
August 29, 2024
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows...
Via
Benzinga
Exposures
Product Safety
argenx to Present at Upcoming Investor Conferences
August 28, 2024
From
argenx SE
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
August 12, 2024
Via
Benzinga
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
August 06, 2024
Via
Benzinga
Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
July 29, 2024
Via
Benzinga
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
July 25, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
July 18, 2024
From
argenx SE
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.